Nationwide Survey of Aggressive NK-cell leukemia: multi-center retrospective study in Japan

Nationwide Survey of Aggressive NK-cell leukemia: multi-center retrospective study in Japan - ANKL22

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046096

Enrollment

Registered

2021-11-17

Start date

2022-11-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aggressive NK-cell leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ANKL cases including those transformed from chronic active Epstein-Barr virus infection or chronic NK-cell lymphoproliferative disease, diagnosed between January 1985 and December 2021. The diagnosis is based on WHO classification revised 4th edition.

Exclusion criteria

Exclusion criteria: Case which diagnosis is not matched with the diagnostic criteria of aggressive NK-cell leukemia suggested in WHO classification /Case which is withdrawn to register this study

Design outcomes

Primary

Measure	Time frame
Overall survival (OS)	—

Secondary

Measure	Time frame
Progression-free survival (PFS) /Overall response rate, complete response rate, best overall response, OS, PFS, duration of response (DOR) of patients who received chemotherapy or stem cell transplantation /Risk factors on survival time /To establish a database of patients with aggressive NK-cell leukemia by integrating with the ANKL07 database /To analyze a transition of probability, patient characteristics, treatment, and prognosis /To compare patient characteristics, treatment, response rate, prognosis of patients with extranodal NK-cell lymphoma, nasal type and aggressive NK-cell leukemia /Genome analysis of aggressive NK-cell leukemia	—

Measure

Time frame

Progression-free survival (PFS) /Overall response rate, complete response rate, best overall response, OS, PFS, duration of response (DOR) of patients who received chemotherapy or stem cell transplantation /Risk factors on survival time /To establish a database of patients with aggressive NK-cell leukemia by integrating with the ANKL07 database /To analyze a transition of probability, patient characteristics, treatment, and prognosis /To compare patient characteristics, treatment, response rate, prognosis of patients with extranodal NK-cell lymphoma, nasal type and aggressive NK-cell leukemia /Genome analysis of aggressive NK-cell leukemia

—

Countries

Japan

Contacts

Public ContactAyumi Fujimoto

Shimane University Hospital Department of Hematology

afujimot@med.shimane-u.ac.jp0853-20-23088

Outcome results